MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its novel prostate cancer genomic testing solutions are SelectMDx, a non-invasive urine test; and ConfirmMDx, an epigenetic test, which provide physicians with a clinical pathway to identify clinically prostate cancer while minimizing the use of invasive procedures that are prone to complications. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.
Frequently asked questions
What sector does Mdxhealth (MDXH) operate in?
Mdxhealth belongs to the Healthcare sector and operates in the Diagnostics & Research industry.
What is Mdxhealth (MDXH) current stock price?
As of the latest data, Mdxhealth stock price is €0.30, with a previous close of €0.29. Mdxhealth gained €0.01 in the last trading session, representing a 2.42% increase.
What is Mdxhealth (MDXH) current market capitalization?
Mdxhealth market cap is approximately 85.63 million.
What is Mdxhealth (MDXH) Earnings Per Share (EPS)?
The trailing EPS is -€1.91, and the forward EPS is -€4.61.
Does Mdxhealth (MDXH) pay dividends?
No. Mdxhealth does not pay a dividend.
What is Mdxhealth (MDXH) beta (volatility) score?
Mdxhealth has a beta of 0.794, indicating lower volatility than the overall market.
